Adaptive Biotechnologies Corporation
ADPT
$24.66
$0.321.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 308.08M | 295.41M | 276.98M | 252.75M | 205.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 308.08M | 295.41M | 276.98M | 252.75M | 205.22M |
| Cost of Revenue | 163.46M | 166.28M | 165.13M | 166.38M | 165.38M |
| Gross Profit | 144.62M | 129.13M | 111.85M | 86.38M | 39.83M |
| SG&A Expenses | 180.38M | 174.16M | 167.27M | 162.87M | 159.25M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 345.54M | 342.13M | 334.10M | 330.94M | 326.33M |
| Operating Income | -37.46M | -46.73M | -57.12M | -78.19M | -121.11M |
| Income Before Tax | -63.99M | -49.64M | -59.46M | -79.60M | -121.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.99 | -49.64 | -59.46 | -79.60 | -121.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 136.00K | -38.00K | -42.00K | -17.00K | 8.00K |
| Net Income | -63.85M | -49.68M | -59.50M | -79.61M | -121.23M |
| EBIT | -37.46M | -46.73M | -57.12M | -78.19M | -121.11M |
| EBITDA | -21.33M | -29.79M | -39.29M | -60.10M | -102.84M |
| EPS Basic | -0.40 | -0.32 | -0.39 | -0.53 | -0.81 |
| Normalized Basic EPS | -0.16 | -0.20 | -0.25 | -0.34 | -0.52 |
| EPS Diluted | -0.41 | -0.33 | -0.40 | -0.54 | -0.82 |
| Normalized Diluted EPS | -0.16 | -0.21 | -0.25 | -0.35 | -0.52 |
| Average Basic Shares Outstanding | 620.94M | 613.16M | 606.84M | 601.39M | 596.47M |
| Average Diluted Shares Outstanding | 631.67M | 623.89M | 617.57M | 612.12M | 596.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |